TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Legend Biotech ( (LEGN) ) just unveiled an update.
On December 6, 2025, Legend Biotech announced new data from the CARTITUDE studies at the ASH Annual Meeting, highlighting the long-term benefits of CARVYKTI® in treating relapsed/refractory multiple myeloma. The studies showed significant progression-free survival benefits, especially when used earlier in treatment. Additionally, first-in-human results for LUCAR-G39D in non-Hodgkin lymphoma demonstrated promising safety and efficacy. These findings reinforce Legend Biotech’s position in the cell therapy market and suggest potential improvements in patient outcomes.
The most recent analyst rating on (LEGN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s strong revenue growth and positive earnings call sentiment are overshadowed by significant profitability and cash flow challenges. The technical indicators suggest bearish momentum, and the valuation is unattractive due to ongoing losses. While there are growth opportunities, the company must address these financial and operational issues to improve its stock attractiveness.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a global leader in cell therapy, focusing on innovative treatments for hematological malignancies. The company is known for its CAR-T cell therapies, particularly CARVYKTI®, which targets multiple myeloma and non-Hodgkin lymphoma.
Average Trading Volume: 1,507,157
Technical Sentiment Signal: Sell
Current Market Cap: $5.2B
See more insights into LEGN stock on TipRanks’ Stock Analysis page.